296 related articles for article (PubMed ID: 7890396)
1. Protective immunity induced by Bacillus anthracis toxin-deficient strains.
Pezard C; Weber M; Sirard JC; Berche P; Mock M
Infect Immun; 1995 Apr; 63(4):1369-72. PubMed ID: 7890396
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Taft SC; Weiss AA
Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
[TBL] [Abstract][Full Text] [Related]
3. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
Welkos S; Little S; Friedlander A; Fritz D; Fellows P
Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
[TBL] [Abstract][Full Text] [Related]
4. Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis.
Brossier F; Weber-Levy M; Mock M; Sirard JC
Infect Immun; 2000 Oct; 68(10):5731-4. PubMed ID: 10992478
[TBL] [Abstract][Full Text] [Related]
5. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
Price BM; Liner AL; Park S; Leppla SH; Mateczun A; Galloway DR
Infect Immun; 2001 Jul; 69(7):4509-15. PubMed ID: 11401993
[TBL] [Abstract][Full Text] [Related]
6. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
Gaur R; Gupta PK; Banerjea AC; Singh Y
Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
[TBL] [Abstract][Full Text] [Related]
7. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.
Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A
Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664
[TBL] [Abstract][Full Text] [Related]
8. Role of toxin functional domains in anthrax pathogenesis.
Brossier F; Weber-Levy M; Mock M; Sirard JC
Infect Immun; 2000 Apr; 68(4):1781-6. PubMed ID: 10722564
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model.
Varshney A; Kumar M; Nagar DP; Pal V; Goel AK
Biologicals; 2019 Sep; 61():38-43. PubMed ID: 31416791
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel multiepitope chimeric vaccine against anthrax.
Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
[TBL] [Abstract][Full Text] [Related]
11. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW
FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
[TBL] [Abstract][Full Text] [Related]
12. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H
Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276
[TBL] [Abstract][Full Text] [Related]
13. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
14. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
[TBL] [Abstract][Full Text] [Related]
15. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
[TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
[TBL] [Abstract][Full Text] [Related]
17. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
18. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
19. CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.
Devera TS; Aye LM; Lang GA; Joshi SK; Ballard JD; Lang ML
Infect Immun; 2010 Apr; 78(4):1610-7. PubMed ID: 20123711
[TBL] [Abstract][Full Text] [Related]
20. Contribution of individual toxin components to virulence of Bacillus anthracis.
Pezard C; Berche P; Mock M
Infect Immun; 1991 Oct; 59(10):3472-7. PubMed ID: 1910002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
